Why the FDA should not approve an ineffective multicancer screening test
An FDA advisory committee supports approving Grail's multicancer screening test, despite opposition from a cancer screening researcher who argues the test is ineffective and that taxpayers should not fund it. Concurrently, blood tests capable of screening for over fifty forms of cancer are available in Houston and are being studied by OHSU researchers. Questions surrounding cancer screening efficacy persist as discussions grow about regulatory approval standards and patient utilization. Financial markets are also reacting, with biotech stocks related to cancer screening gaining attention from commentators like Jim Cramer.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ An FDA advisory committee recommends approving Grail's multi-cancer screening test.
- ✓ A cancer screening researcher disagrees with the FDA advisory committee recommendation.
- ✓ A blood test offered in Houston screens for over 50 forms of cancer.
- ✓ OHSU researchers are studying a blood test to detect cancer.
What changed
An FDA advisory committee recommended approval for Grail's multicancer screening test over the objections of a cancer screening researcher.
Live updates
-
FDA Advisory Committee Recommends Grail Multicancer Test
An FDA advisory committee supports approving Grail's multicancer screening test, despite opposition from a cancer screening researcher who argues the test is ineffective and that taxpayers should not fund it. Concurrently, blood tests capable of screening for over fifty forms of cancer are available in Houston and are being studied by OHSU researchers. Questions surrounding cancer screening efficacy persist as discussions grow about regulatory approval standards and patient utilization. Financial markets are also reacting, with biotech stocks related to cancer screening gaining attention from commentators like Jim Cramer.
Why it matters
Multicancer blood tests represent a significant shift in oncology by attempting to detect dozens of malignancies from a single draw. However, critics question whether these tools deliver reliable clinical benefits or merely inflate health care utilization without improving patient outcomes. The Food and Drug Administration faces mounting scrutiny over how it evaluates diagnostic efficacy before granting clearance.
What is confirmed
- An FDA advisory committee recommends approving Grail's multi-cancer screening test.
- A cancer screening researcher disagrees with the FDA advisory committee recommendation.
- A blood test offered in Houston screens for over 50 forms of cancer.
- OHSU researchers are studying a blood test to detect cancer.
Still unconfirmed
- Taxpayers should not pay for an ineffective multi-cancer screening test.
What to watch next
- Final FDA decision on the approval of Grail's multicancer screening test
- Further clinical data regarding the effectiveness of multicancer blood screening tests
confidence 90%Sources used for this update (7)
- www.statnews.com — Taxpayers shouldn’t pay for an ineffective multi-cancer ...
- STAT — Why the FDA should not approve an ineffective multicancer screening test
- KHOU — Blood test offered in Houston screens for 50+ forms of cancer, but there are limitations
- CNBC — This buzzy biotech stock is up 60% this year. Cramer's advice on building a stake
- Yahoo Finance — Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)
- KOBI-TV NBC5 / KOTI-TV NBC2 — OHSU researchers study blood test to detect cancer - KOBI-TV NBC5 / KOTI-TV NBC2
- www.statnews.com — Are AI tools inflating health care costs for no reason? | STAT
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community